Alexion and Affibody Announce Partnership to Co-Develop Anti-FcRn Affibody Molecule
Alexion Pharmaceuticals and Affibody AB announced a partnership to co-develop ABY-039 for rare Immunoglobulin G (IgG)-mediated autoimmune diseases. Currently in Phase 1 development,…
Read More...
Read More...
